ISRCTN59482963已完成未知
To compare intravenous treosulphan with intravenous treosulphan plus cisplatin in advanced ovarian cancer
eo Pharmaceuticals0 个研究点目标入组 0 人开始时间: 2002年8月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. International Federation of Gynecology and Obstetrics (FIGO) stage Ic or II (except well differentiated), III or IV ovarian cancer
- •2. Histological confirmation of carcinoma of epithelial origin
- •3. Aged 75 or under
- •4. Life expectancy >2 months
- •5. No extensive prior chemotherapy (no prior treosulfan or cisplatin at all, and not more than one course of other cytotoxic treatment)
- •6. No radical prior radiotherapy to pelvis and/or abdomen within preceding 3 months
- •7. No depressed marrow function or gastro-intestinal bleeding
- •8. Good renal function
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
1 期
TREOSULFAN LEVELS IN CHILDREN UNDERGOING STEM CELL TRANSPLANTATIOAny paediatric disease with an indication to an allogeneic stem cell transplantation (inclusing leukaemia, primary immunodeficiencies, metabolic disorders and autoimmune or genetic inflammatory bowel disorders).EUCTR2013-003257-20-GBGREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST90
已完成
3 期
Treosulfan oral versus intravenous in recurrent ovarian cancer. An open-label, randomized, controlled, phase 3-b clinical trialC56Malignant neoplasm of ovaryDRKS00003943niversitätsklinikum FreiburgFrauenklinik270
进行中（未招募）
1 期
Conditioning treatment with treosulfan or busulfan for chemotherapy prior to stem cell transplantation in patients with leukemia.EUCTR2008-002356-18-DEmedac Gesellschaft für klinische Spezialpräparate mbH960
进行中（未招募）
1 期
Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens - Clinical Phase III Treosulfan based conditioning vs RICPatients with acute myeloid leukaemia (AML)or myelodysplastic syndrome (MDS) considered ineligible to standard conditioning therapies prior to allogenic stem cell transplantationMedDRA version: 9.1Level: LLTClassification code 10000881Term: Acute myeloid leukaemia (in remission)MedDRA version: 9.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSEUCTR2008-002356-18-ITMEDAC RESEARCH545
进行中（未招募）
1 期
Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens. - Clinical phase III trial of Treosulfan-based conditioning vs. RICPatients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) considered ineligible to standard conditioning therapies prior to allogeneic stem cell transplantation.MedDRA version: 9.1Level: LLTClassification code 10000881Term: Acute myeloid leukaemia (in remission)MedDRA version: 9.1Level: LLTClassification code 10028534Term: Myelodysplastic syndrome NOSEUCTR2008-002356-18-FRmedac Gesellschaft für klinische Spezialpräparate mbH545